CAPHRA Calls for Review of Tobacco Harm Reduction Methods

Dec.13.2022
CAPHRA Calls for Review of Tobacco Harm Reduction Methods
The CAPHRA coalition sent a letter to FCTC representatives urging them to review THR methods for COP10 in Panama.

The Coalition of Asia Pacific Tobacco Harm Reduction Advocates (CAPHRA), which comprises of nine member organizations, has written to chiefs of delegations of the Framework Convention on Tobacco Control (FCTC) worldwide, urging them to review methods supporting the reduction of tobacco harm (THR).


As governments from various countries send representatives to attend the 10th Conference of the Parties (COP10) in November 2023, the CAPHRA Alliance is eager to provide comprehensive reference materials to leaders for COP10 planning, submission and deliberation.


The 10th Conference of the Parties (COP10) will be held in Panama and hosted by the World Health Organization's Framework Convention on Tobacco Control.


We represent four million nicotine product users in the Asia-Pacific region. Our region is particularly vulnerable to the dangers and deaths caused by combustible and unsafe oral tobacco worldwide," the letter stated.


Representatives from the CAPHRA alliance have reminded health leaders that the FCTC convention has the authority to consider harm reduction as a core tobacco control policy.


For decades, it has been widely known that the tar and carcinogens found in tobacco smoke lead to smoking-related deaths and illnesses, rather than nicotine. Studies have shown that although nicotine is generally mildly addictive, like caffeine, it is not a health concern, they wrote.


The letter also calls on representatives to condemn the policy of holding the COP10 conference behind closed doors by the FCTC.


They wrote: "COP10 should represent the rights and wishes of the citizens. Their participation fees are paid by taxpayers and it is hoped that they speak for themselves, recognize the scientific benefits of supporting ENDS for harm reduction, and uphold democratic principles," they wrote.


Representatives of the CAPHRA Alliance are requesting that countries take into account consumers' right to make choices that help them avoid negative health outcomes when submitting their COP10 submissions. Additionally, smokers have the right to access nicotine products with lower harm as alternatives to smoking.


A recent white paper titled "Disrupting Public Health: A Consumer Perspective" was presented by Nancy Loucas, the executive coordinator of the CAPHRA alliance, at the 5th Asia Harm Reduction Forum. The evidence-based document was included in the presentation.


2FIRSTS will continue to cover this issue, with updates available on the "2FIRSTS APP". Scan the QR code below to download the app.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Casey’s, the No. 3 U.S. C-Store Chain, Sees Nicotine Category Shift as Pouches Rise 31% and Vapor 12%
Casey’s, the No. 3 U.S. C-Store Chain, Sees Nicotine Category Shift as Pouches Rise 31% and Vapor 12%
Casey’s General Stores (NASDAQ: CASY) reported accelerating growth in modern nicotine products during its fiscal third quarter ended January 31, 2026. Nicotine pouch sales increased 31% year over year, while vapor products rose 12%. Although cigarette unit sales continued to decline, management stated that the rate of decline slowed compared to prior quarters.
Market
Mar.15
Philip Morris Ukraine Says It Will Invest Another USD 10.00 Million in ZYN Nicotine Pouches This Year
Philip Morris Ukraine Says It Will Invest Another USD 10.00 Million in ZYN Nicotine Pouches This Year
Philip Morris said that after investing USD 5.00 million last year to promote its ZYN nicotine pouch brand in Ukraine, it plans to invest another USD 10.00 million this year to develop the nicotine pouch category and launch a new ZYN line.
Apr.08 by 2FIRSTS.ai
PMI Sells Stake in Swedish Match Brazil Business, Including Fiat Lux Brand
PMI Sells Stake in Swedish Match Brazil Business, Including Fiat Lux Brand
Philip Morris International said it is selling its stake in Swedish Match do Brasil, which controls the Brazilian household goods brand Fiat Lux. The buyer is Ignis FIP, a Brazilian private investment vehicle backed by businessman Marcos Fernando Garms. The transaction also includes Swedish Match da Amazônia, but the value of the deal was not disclosed. PMI said the sale is aligned with its vision of a smoke-free future.
Mar.20 by 2FIRSTS.ai
West Virginia House Passes 5% Income Tax Cut and Rejects Vape Tax Increase
West Virginia House Passes 5% Income Tax Cut and Rejects Vape Tax Increase
The West Virginia House of Delegates debates income tax cut bill before session's end, rejecting Senate's e-cigarette tax amendment.With one day left in the legislative session, the West Virginia House spent more than an hour debating amendments to an income tax reduction bill.
Mar.16 by 2FIRSTS.ai
ELFBAR Resolves Global Dispute Over "ELF" Trademark with VPR Brands LP
ELFBAR Resolves Global Dispute Over "ELF" Trademark with VPR Brands LP
ELFBAR announces global settlement with VPR Brands LP over "ELF" trademark dispute, covering major markets like US, Canada, UK.
Apr.01 by 2FIRSTS.ai
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
U.S.-based medical startup Qnovia Inc. reported positive results from its first-in-human clinical trial of RespiRx, an inhalable nicotine replacement therapy (NRT) device designed to support smoking cessation.
Innovation
Feb.24